The Expression Of SNCG And Its Clinical Significance In Ovarian Cancer

Objective:By studying the differences in the expression levels of SNCG between normal ovarian tissues and ovarian cancer tissues,then to analyze the expression status of SNCG protein in human ovaries cancer.Further analyzing the correlation with the expression of SNCG in ovarian cancer and its clinicopathological features,recurrence,chemotherapy treatment effect,in order to provide a specific monitoring index for clinical diagnosis and treatment of ovarian cancer patients.Methods: 1.Retrospective collected the paraffin section of 119 ovarian cancer patients and 50 cases of normal ovarian which diagnosed in the First Affiliated Hospital of Shihezi University Medical College from January 2010 to January 2015,then collected their complete clinical and pathological data.2.Using immunohistochemical method to detecte the expression of SNCG in ovarian cancer tissues and normal ovarian tissues.3.Using SPSS22.0 software to analyze the collected data.The statistical data were analyzed by hypothesis test,and Pearson chi-square test was used to analyze the relationship between the difference of SNCG protein expression status in ovarian cancer tissues and the clinicopathological characteristics.The survival analysis curve was plotted by Kaplan-Meier method and tested by Log-rank test.Cox proportional risk model was used for multivariate survival analysis.Results:1.Totally collected 119 ovarian cancer patients and 50 normal ovarian patients,we gather their clinicopathological data and paraffin sections.Including 89 cases of serous carcinoma,3 cases of clear cell carcinoma,4 cases of mucinous carcinoma,9 cases of other types,and 14 cases of endometrioid carcinoma.III period With 65 cases,IV period for 14 cases,II period for 22 cases,I period for 12 cases and 6 cases of unknown in phases.Immunohistochemical staining showed that SNCG was negative expressed in normal ovarian tissue,then the positive rate of SNCG expression in ovarian tissue was 72.3%(86/119),and the difference was statistically significant(P < 0.001).2.The relationship between the expression of SNCG and clinical data of 113 patients with ovarian cancer was analyzed.It was found that the expression of SNCG was not related to the age,primary site and ascites of the ovarian cancer patients,P > 0.05.It was correlated with tumor stage,differentiation degree,lymph node metastasis,satisfactory tumor reduction,CA125 and HE4 levels in ovarian cancer patients,P < 0.05.In these SNCG express positive patients,including for 73 cases of serous ovarian cancer(84.9%),high grade serous ovarian cancer 60 cases(69.8%),III-IV patients 68 cases(79.1%),for 60 patients with lymph node metastasis(69.8%),for 55 cases with CA125 of 175 u/m L(64.0%),HE4 acuity 172 pmol/L for 62cases(72.1%),with ascites for 64 cases(74.4%).The expression of SNCG showed a high-risk clinical pathological features of ovarian cancer patients.3.The relationship between the expression of SNCG and recurrence and chemotherapy resistance in ovarian cancer patients was further analyzed.Among the patients with positive SNCG expression,53 cases(63.9%)had recurrence,30 cases(46.1%)had no recurrence,34 cases(41.0%)were platinum-resistant,and 49cases(59.0%)were platinum-sensitive.In the patients with negative SNCG expression,there were 21 cases(70.0%)with recurrence,9 cases(30.0%)without recurrence,13 cases(43.3%)with platinum resistance,and 17 cases(56.7%)with platinum sensitivity.There were no statistically significant differences(P >0.05).4.In order to investigae the association between SNCG protein expression and prognosis in ovarian cancer patients,showed that median PFS was 19 months(95%CI: 15-24 months)and median OS was 40 months(95%CI: 36-48 months)in enrolled ovarian cancer patients.Survival analysis shows that SNCG expression status has nothing to do with PFS,OS in ovarian cancer patients,P > 0.05,The multivariate Cox proportional risk model was analyzed,by using the expression of SNCG in ovarian cancer patients as the main predictor and regulating the clinical factors related to SNCG expression(CA125,HE-4,ascasces,tumor stage,satisfactory cell tumor reduction),and in the analysis of PFS,SNCG expression(HR 1.02595% CI 0.516-1.428 P=0.557),in the analysis of OS,the expression of SNCG(HR 1.075 95% CI0.644-1.794 P=0.783).The correlation between the prognosis of HGSOC patients and the expression state of SNCG was further analyzed,and the results showed that it was correlated with the PFS and OS of HGSOC patients,P=0.007 and P=0.047,respectively.Cox proportional risk model analysis showed PFS(HR 2.107 95%CI 1.014-3.795 P=0.034)and OS(HR 1.238 95%CI 0.716-1.928 P=0.047).The overexpression of SNCG protein can be an independent prognostic factor in HGSOC patients.Conclusions: 1.SNCG is overexpressed in ovarian malignant tumors,moreover,the level of its expression was correlated with the high-risk clinicopathological characteristics of ovarian cancer patients.2.The expression of SNCG has nothing to do with recurrence,chemotherapy resistance of ovarian cancer patients,but it can be used as an independent prognostic factor in HGSOC patients,providing a new research direction for prognosis judgment and clinical treatment of HGSOC patients.